What has happened to utilization and costs for mental health and substance use disorder benefits as the mental health parity laws and associated rules were slowly rolled out?

Beyond the impact of the final rule, IMDs will continue to be a topic of interest to state policy makers as they bolster the continuum of behavioral health and substance use disorder services.

This study assesses the prevalence and costs associated with comorbid chronic medical conditions among individuals with diagnosed opioid use disorder (OUD) and opioid super-users without diagnosed OUD.

A discussion of trends, including recent federal and state laws affecting health insurance benefits for transgender individuals and health insurance clinical coverage policies related to gender reassignment surgery.

This paper presents a comparison of opioid prescription drug patterns among diagnosed and non-diagnosed opioid use disorder populations.

Over 25 million American adults report suffering from daily chronic pain. The increasing use of opioids in recent years has taken a human toll, leading to a rising number of overdose deaths and diagnoses of opioid use disorder.

Many patients with opioid use disorder have complex healthcare needs, contributing to their significant healthcare costs.

The state of Colorado has implemented behavioral healthcare in primary medical care settings under a Centers for Medicare and Medicaid Services State Innovation Model Award.

Nonquantitative treatment limitations continue to be a source of difficulty for many health plans in attaining compliance with the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008.

Final rules clarify how to comply with provisions of the Mental Health Parity and Addiction Equity Act of 2008.

Stoddard Davenport and Joseph Boschert discuss their latest research on opioid use in the United States, including underdiagnoses and how advanced analytics can help predict whether a patient may develop opioid use disorder.